No difference between prednisolone and dexamethasone treatment in bone mineral density and growth in long term survivors of childhood acute lymphoblastic leukemia
| Autor: | Rob Pieters, Friederike G.A.J. Hakvoort-Cammel, Sabine M.P.F. de Muinck Keizer-Schrama, Inge M. van der Sluis, Robert D. van Beek, Marry M. van den Heuvel-Eibrink, Eric P. Krenning |
|---|---|
| Přispěvatelé: | Pediatrics, Radiology & Nuclear Medicine |
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Antineoplastic Agents Hormonal medicine.drug_class medicine.medical_treatment Prednisolone Urology Growth Dexamethasone Fractures Bone Bone Density Internal medicine Acute lymphocytic leukemia Medicine Humans Survivors Child Netherlands Bone mineral Chemotherapy Acute leukemia business.industry Infant Hematology Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Endocrinology Cross-Sectional Studies Oncology Child Preschool Pediatrics Perinatology and Child Health Lean body mass Body Composition Corticosteroid Regression Analysis Female business medicine.drug |
| Zdroj: | Pediatric Blood & Cancer, 46, 88-93. Wiley-Liss Inc. |
| ISSN: | 1545-5017 1545-5009 |
| Popis: | Background Dexamethasone is known to have both more potent leukemic activity and is associated with a higher incidence of side effects than prednisolone. In this study, we compared the long-term effects of dexamethasone and prednisolone on bone mineral density (BMD), body composition and growth in long-term survivors of ALL in first complete remission. Procedure Ninety patients (51 male, 49 female; 8.6–38.5 year), treated with either a prednisolone containing protocol (n = 47; n = 19 also with CNS-irradiation) or a dexamethasone containing protocol (n = 43; no cranial irradiation) participated in this cross-sectional single center study. Mean follow-up was 12.7 years (2.0–29.7 years). BMD of lumbar spine and total body, and body composition were expressed as standard deviation scores (SDS) using dual energy X-ray absorptiometry. Bone mineral apparent density of the lumbar spine (BMAD) was calculated to correct for bone size. Results There was no difference in height, height corrected for target height, BMD, or lean body mass between prednisolone and dexamethasone treated patients. Prednisolone treated patients had an increased percentage body fat (SDS +0.46; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text